DiaMedica (TSX VENTURE:DMA) is pleased to announce that Mark Robbins, Ph.D.,
J.D., has joined as Vice President, Clinical and Regulatory Affairs to oversee
DiaMedica's clinical programs. Dr. Robbins has over 30 years of experience in
biopharmaceutical drug development with broad therapeutic experience in
endocrine/metabolic, cardiology, neurology, dermatology, and oncology. Dr.
Robbins has developed and successfully implemented regulatory/clinical
strategies leading to 11 successful NDA/BLA approvals.


"We are very fortunate to be have recruited someone of Mark's history,
reputation and capability to this key role at DiaMedica," said Rick Pauls,
Chairman and CEO. "His tremendous depth of experience will support our strategy
in designing and managing clinical trials and regulatory aspects as DiaMedica
moves its lead products from the development stage through manufacturing and
into clinical trials."


"The drugs currently in development at DiaMedica could significantly improve the
lives of millions of patients, and I look forward to advancing these compounds
aggressively through the clinic," stated Mark Robbins, Ph.D., J.D., "I am
enthusiastic to help DiaMedica achieve its goals of commercial success and
continued growth."


Dr. Robbins was most recently President & CEO of Kodiak Strategic Consultants,
which provides strategic clinical, regulatory and business development
consultation to biotechnology companies, and President & CEO of Tychon
Bioscience, Inc. a targeted drug delivery biotech venture. Dr. Robbins spent 15
year with Upsher-Smith Laboratories, advancing to Executive Vice President,
Legal, Scientific and Technical Operations, Chief Scientific Officer and
Assistant Secretary, where he oversaw the clinical and regulatory strategies for
several drugs ranging from R&D to manufacturing and Phase I to Phase III.
Previous to this role, Dr. Robbins spent 13 years at Mallinckrodt Group, Inc.,
advancing to Director of Medical Affairs.


The Company issued Dr. Robbins 200,000 stock options in accordance with the
Stock Option Plan at an exercise price of $1.25 and a term of 10 years. The
options are subject to acceptance by the TSX Venture exchange.


About DiaMedica

DiaMedica Inc. is a publicly traded (TSX VENTURE:DMA) biopharmaceutical company
focused on the discovery and development of novel therapies to treat diabetes
and the complications associated with diabetes. DiaMedica's lead compound,
DM-199, is a recombinant human protein that represents a novel approach to
treating Type 1 and Type 2 diabetes. Based on the Company's understanding of the
postprandial state, DiaMedica is also developing a novel monoclonal antibody,
DM-204 for the treatment of Type 2 diabetes. Chronic treatment with DM-204 in a
pre-clinical Type 2 diabetes model resulted in a significant improvement in
blood glucose control as measured by HbA1c and also significant improved blood
pressure and serum cholesterol levels.


The Company is listed on the TSX Venture Exchange in Canada under the trading
symbol 'DMA'.


FORWARD-LOOKING STATEMENTS

The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, should be considered forward-looking statements. Such statements
are based on management's exercise of business judgment as well as assumptions
made by and information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe", "estimate",
"expect", "intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as contained in the
Corporation's filings with Canadian securities regulatory authorities. Should
one or more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Corporation undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize.


FOR FURTHER INFORMATION PLEASE CONTACT: 
DiaMedica Inc.
Rick Pauls
Chairman & CEO
763-710-4455
info@diamedica.com
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more DiaMedica Inc. Charts.
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more DiaMedica Inc. Charts.